Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of SCY-635, Pegasys and Copegus in Hepatitis C
This study has been completed.
Study NCT01265511   Information provided by Scynexis Incorporated

First Received on November 23, 2010.   Last Updated on May 29, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C Infection
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Placebo
SCY-635
peginterferon alfa 2a
Ribavirin
Additional drug interventions recognized in this trial
Interferon-alpha
Peginterferon alfa-2a
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Scynexis Incorporated


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services